Drawing for ADVANTAGE

USPTO serial 73833803

ADVANTAGE

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
GOODPASTER, SCOTT
Law office
FILE REPOSITORY (FRANCONIA)

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with ADVANTAGE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

MURRAY SCHAFFER

MURRAY SCHAFFER BAUER & SCHAFFERSTE 344 114 OLD COUNTRY RDMINEOLA, NY 11051-4477UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
010A RAPID ENZYME IMMUNOASSAY TEST FOR QUALITATIVE DETECTION OF OPIATES IN URINE; A SOLID-PHASE ENZYME IMMUNOASSAY FOR THE DETECTION OF CREATINE KINASE FOR MUSCLE AND FOR BRAIN (CK-MB); A SOLID PHASE ENZYME IMMUNOASSAY FOR THE DETECTION OF REBELLA IGG ANTIBODIES IN SERUM OR PLASMA; A RAPID SOLID-PHASE ENZYME IMMUNOASSAY TEST FOR QUANTITATIVE DETECTION OF HUMAN CHORIONIC GONADOTROPHIC (HCG) SERUM AND PLASMA; A RAPID ENZYME IMMUNOASSAY TEST FOR QUALITATIVE DETECTION OF HUMAN CHORIONIC GONADOTROPHIN (HCG) IN URINE, SERUM AND PLASMA; A VERY RAPID (10-MINUTE) SOLID-PHASE IMMUNOASSAY TEST FOR THE QUANTITATIVE DETERMINATION OF HUMAN VENTRICUL 1 (HVMLC1) IN HUMAN SERUM; AN ENZYME IMMUNOASSAY TEST FOR THE QUANTITATION OF THYROXINE STIMULATING HORMONE (TSH) IN SERUM OR PLASMA; AN ENZYME IMMUNOASSAY TESMONONUCLEOSIS (IM), RHEUMATOID FACTOR (RF), LUPUS ERYTHEMATOSUS (LE), STREPTOCOCCAL INFECTION (ASO-PLUS), INFLAMMATION AND PREGNANCY; AN ASSAYED HUMAN URINE FORTIVE DETECTION AND CONFIRMATION OF GROUP A STREPTOCOCCAL ANTIGEN FROM THROAT SWABS; A SOLID-PHASE ENZYME IMMUNOASAY CONDUCTED AT A MEMBRANE SURFACE FOR DIRECT DETECTION OF C-REACTIVE PROTEIN (CRP); RAPID (FOUR MINUTE) SOLID-PHASE ENZYME TEST FOR QUALITATIVE AND QUANTITATIVE DECTECTION OF HETEROPHILE ANTIBODIES ASSOCIATABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (ABN2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Sep 20, 1990ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jan 29, 1990CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 20, 1989DOCKASSIGNED TO EXAMINER—
Dec 19, 1989DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance